Free Trial
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

Galera Therapeutics logo
$0.04 0.00 (0.00%)
(As of 11/21/2024 ET)

About Galera Therapeutics Stock (NASDAQ:GRTX)

Key Stats

Today's Range
$0.04
$0.05
50-Day Range
$0.04
$0.08
52-Week Range
$0.04
$0.29
Volume
18,923 shs
Average Volume
1.17 million shs
Market Capitalization
$2.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GRTX Stock News Headlines

Can Trump Make Housing Great Again?
Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflation soared 20%... Which could be the final blow for the American Dream - even with Trump in office.
Newron Pharmaceuticals S.p.A. (NP5.DE)
GRTX Galera Therapeutics, Inc.
See More Headlines

GRTX Stock Analysis - Frequently Asked Questions

Galera Therapeutics' stock was trading at $0.1454 on January 1st, 2024. Since then, GRTX shares have decreased by 71.8% and is now trading at $0.0410.
View the best growth stocks for 2024 here
.

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.15.

Galera Therapeutics (GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), NextEra Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP).

Company Calendar

Last Earnings
11/10/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-59,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.41) per share

Miscellaneous

Free Float
50,639,000
Market Cap
$2.23 million
Optionable
Optionable
Beta
1.99
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:GRTX) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners